Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.

Carr A, Mngqibisa R, Khaertynova I, et al. AIDS. 2025;40(2):189-197.

Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges.

Christopoulos KA, Hickey MD, Rana A. Curr Opin HIV AIDS. 2025;20(1):11-18.

Early experience implementing long-acting injectable cabotegravir/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-funded clinic in the US South.

Collins LF, Corbin-Johnson D, Asrat M, et al. Open Forum Infect Dis. 2022;9(9):ofac455.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.

Mechanisms of motivational interviewing for antiretroviral medication adherence in people with HIV.

Hogan A, Catley D, Goggin K, Evangeli M. AIDS Behav. 2020;24(10):2956-2965.

Mechanisms of motivational interviewing for antiretroviral medication adherence in people with HIV.

Hogan A, Catley D, Goggin K, et al. AIDS Behav. 2020;24(10):2956-2965.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.

Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years.

Margot NA, Jogiraju V, Pennetzdorfer N, et al. J Infect Dis. 2025;231(5):1239-1245.

Subcutaneous lenacapavir in people with multidrug-resistant HIV-1: 156 week results of the CAPELLA study.

Ogbuagu O, Wiznia A, McGowan JP, et al. Open Forum Infect Dis. 2025;13(1):ofaf763.

A randomized trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: final 96-week results of the D2EFT study.

Nyein PP, Borok M, Eriobu N, et al. Clin Infect Dis. 2026;81(6):e568-e580.

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

Paton NI, Musaazi J, Kityo C, et al. Lancet HIV. 2022;9(6):e381-e393.

Cabotegravir plus rilpivirine for persons with HIV and adherence challenges.

Rana AI, Zheng L, Castillo-Mancilla J, et al. N Engl J Med. 2026;394(9):858-871.

HIV viral suppression with use of long-acting antiretroviral therapy in people with and without initial viremia.

Spinelli MA, Heise MJ, Gistand N, et al. JAMA. 2025;333(16):1451-1453.